Comparison of the effectiveness of extracorporeal shock wave therapy and high-intensity laser therapy in patients with knee osteoarthritis: a single-blind randomized clinical trial - Scorecard - MDSpire
Advertisement
Comparison of the effectiveness of extracorporeal shock wave therapy and high-intensity laser therapy in patients with knee osteoarthritis: a single-blind randomized clinical trial
Clinical Scorecard: Evaluation of Extracorporeal Shock Wave Therapy versus High-Intensity Laser Therapy for Treating Knee Osteoarthritis: Results from a Single-Blind Randomized Clinical Trial
At a Glance
Category
Detail
Condition
Knee Osteoarthritis
Key Mechanisms
ESWT delivers high-energy acoustic waves triggering mechanotransduction to promote tissue regeneration and angiogenesis; HILT uses high-intensity laser to increase local blood circulation, tissue regeneration, and reduce pain and edema
Target Population
Patients aged 40–75 years with primary knee osteoarthritis, Kellgren-Lawrence stage 2–3, with knee pain ≥6 months and VAS ≥3
Care Setting
Outpatient clinical setting with physical therapy modalities
Key Highlights
Osteoarthritis is a degenerative joint disease causing pain, stiffness, and disability, commonly affecting the knee.
ESWT and HILT are non-invasive physical therapy modalities with distinct biological mechanisms beneficial for knee OA.
This single-blind randomized clinical trial directly compares ESWT and HILT effectiveness on pain and function in knee OA patients.
Guideline-Based Recommendations
Diagnosis
Use American College of Rheumatology criteria for diagnosing primary knee osteoarthritis.
Assess radiological severity with Kellgren-Lawrence classification (stage 2–3 included).
Evaluate pain using Visual Analog Scale (VAS).
Assess function with WOMAC and Lequesne indices.
Management
Consider non-pharmacological treatments including ESWT and HILT as adjuncts to exercise therapy.
ESWT may be used to stimulate tissue regeneration and reduce inflammation via mechanotransduction.
HILT may be applied to improve local circulation, reduce pain, and promote tissue healing.
Exclude patients with inflammatory arthritis, recent knee surgery, or recent intra-articular injections.
Monitoring & Follow-up
Evaluate clinical outcomes before treatment, immediately after (2 weeks), and at 6 weeks post-treatment.
Monitor pain levels using VAS and functional status using WOMAC and Lequesne indices.
Perform radiological assessments as needed to monitor disease progression.
Risks
Contraindications include inflammatory arthritis, recent knee surgery or trauma, pregnancy, bleeding diathesis, and systemic inflammatory diseases.
Careful patient selection is essential to avoid adverse effects.
Patient & Prescribing Data
Adults aged 40–75 years with primary knee osteoarthritis, moderate severity (Kellgren-Lawrence stage 2–3), and chronic knee pain.
Both ESWT and HILT are effective non-invasive therapies for reducing pain and improving function in knee OA; direct comparative data supports their use tailored to patient needs and contraindications.
Clinical Best Practices
Confirm diagnosis of knee OA using standardized clinical and radiological criteria before initiating therapy.
Use validated pain and functional assessment tools (VAS, WOMAC, Lequesne) to monitor treatment response.
Apply ESWT and HILT as adjuncts to exercise therapy for optimal clinical outcomes.
Exclude patients with contraindications such as inflammatory arthritis or recent knee interventions.
Ensure informed consent and adherence to ethical standards in clinical trials and practice.
In a UK cohort, patients with osteoarthritis who initiated centrally acting analgesics had a higher hazard of knee or hip replacement than those who initiated SSRIs, though residual confounding by pain severity remains a key limitation.
